Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$395.95 USD

395.95
140,093

+2.04 (0.52%)

Updated Jun 17, 2024 04:00 PM ET

After-Market: $396.49 +0.54 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.

Medpace Holdings (MEDP) Sees Hammer Chart Pattern: Time to Buy?

Medpace Holdings (MEDP) has been struggling lately, but the selling pressure may be coming to an end soon.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.

Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools

Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.

Here's Why You Should Retain Boston Scientific (BSX) for Now

Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.

Patterson Companies (PDCO) Beats on Q2 Earnings & Revenues

Patterson Companies' (PDCO) fiscal second-quarter 2022 results benefit from strength in the Animal Health segment.

Walgreens (WBA) Buys Remaining Stake in German Wholesale Business

Walgreens' (WBA) recent acquisition of the remaining ownership stake helps the company to further solidify its position as a leading pharmaceutical wholesaler in Germany.

Medpace (MEDP) Upgraded to Strong Buy: Here's What You Should Know

Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable

Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.

SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System

SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.

Here's Why You Should Retain Abbott (ABT) Stock For Now

Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Bio Rad (BIO) Grows Internationally on New Product Launches

Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.

CVS Health (CVS) Installs Time-Delay Safes in Texas Pharmacies

CVS Health's (CVS) time-delay safes reduce theft and diversion of opioid medications and boost the security of stores, creating a safe environment for patients and staff.

Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?

Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Smith+Nephew (SNN) Rolls Out Robotic Assisted Surgical System

Smith+Nephew's (SNN) CORI system enables each patient to have a knee replacement that is shape-matched and aligned to their specific anatomy.

Urmimala Biswas headshot

Medtronic's (MDT) Q2 Earnings Beat, Revenues Lag Estimates

Medtronic (MDT) cuts revenue growth guidance for the full year on the projection of a severe pandemic impact to continue through the rest of the year.

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Illumina's (ILMN) New Alliance to Accelerate Genomics in China

Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Veeva Systems (VEEV) Digital Tools Boost Patient Engagement

Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams.

Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).